Jennifer Furin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jennifer Furin has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Erica Lessem
2 shared publicationsI. Kalandadze
§David Agmashenebeli University of Georgia, Tbilisi, Georgia
2 shared publicationsM. Gegia
United States Agency for International Development Georgia TB Prevention Project, Tbilisi, Georgia
2 shared publicationsA C Miller
Harvard Medical School, Department of Global Health and Social Medicine
1 shared publicationA. Diacon
Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, South Africa
1 shared publicationA. Golubkov
Partners In Health–Russia, Boston, Massachusetts, USA
1 shared publication
Latest Publications
- 1 December 2020
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 34 (4) , 863-886
Drug-Resistant Tuberculosis
- 1 December 2020
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 34 (4) , 863-886
Drug-Resistant Tuberculosis
- 1 August 2019
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 23 (8) , 959
A human rights-based approach to tuberculosis diagnosis
- 1 August 2019
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 23 (8) , 959
A human rights-based approach to tuberculosis diagnosis
- 1 April 2018
- Published by Elsevier in The Lancet Child & Adolescent Health
- Vol. 2 (4) , 237-238
Drug-resistant tuberculosis: will grand promises fail children and adolescents?
- 1 April 2018
- Published by Elsevier in The Lancet Child & Adolescent Health
- Vol. 2 (4) , 237-238
Drug-resistant tuberculosis: will grand promises fail children and adolescents?
- 13 February 2018
- Published by Springer Nature in Current Treatment Options in Infectious Diseases
- Vol. 10 (1) , 90-106
Optimal Management of Drug-Resistant Tuberculosis and Human Immunodeficiency Virus: an Update
- 13 February 2018
- Published by Springer Nature in Current Treatment Options in Infectious Diseases
- Vol. 10 (1) , 90-106
Optimal Management of Drug-Resistant Tuberculosis and Human Immunodeficiency Virus: an Update
- 1 November 2016
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (11) , 6591-6599
Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis
AZD5847 is an oxazolidinone antibiotic with in vitro activity against Mycobacterium tuberculosis . The objective of this study was to evaluate the antimycobacterial activity, safety, and pharmacokinetics of AZD5847 in patients with pulmonary tuberculosis. Groups of 15 treatment-naive, sputum smear-positive adults with pulmonary tuberculosis were randomly assigned to receive AZD5847 at one of four doses (500 mg once daily, 500 mg twice daily, 1,200 mg once daily, and 800 mg twice daily) or daily standard chemotherapy. The primary efficacy endpoint was the mean daily rate of change in the log 10 number of CFU of M. tuberculosis per milliliter of sputum, expressed as the change in log 10 number of CFU per milliliter of sputum per day. The mean 14-day activity of the combination of isoniazid, rifampin, ethambutol, and pyrazinamide (−0.163 log 10 CFU/ml sputum/day; 95% confidence interval [CI], −0.193, −0.133 log 10 CFU/ml sputum/day) was consistent with that found in previous studies. AZD5847 at 500 mg twice daily significantly decreased the number of CFU on solid medium (−0.039; 95% CI, −0.069, −0.009; P = 0.0048). No bactericidal activity was detected at doses of AZD5847 of 500 mg once daily (mean early bactericidal activity [EBA], 0.02 [95% CI, −0.01, 0.05]), 1,200 mg once daily (mean EBA, 0.02 [95% CI, −0.01, 0.05]), and 800 mg twice daily (mean EBA, 0.02 [95% CI, −0.01, 0.05]). AZD5847 at doses of both 500 mg and 800 mg twice daily also showed an increase in the time to a positive culture in MGIT liquid culture medium. Two serious adverse events (grade 4 thrombocytopenia and grade 4 hyperbilirubinemia) occurred in patients receiving AZD5847 at higher doses. AZD5847 dosed twice daily kills tubercle bacilli in the sputum of patients with pulmonary tuberculosis and has modest early bactericidal activity. (This study has been registered at ClinicalTrials.gov under registration no. NCT01516203.)
- 1 November 2016
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (11) , 6591-6599
Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis
AZD5847 is an oxazolidinone antibiotic with in vitro activity against Mycobacterium tuberculosis . The objective of this study was to evaluate the antimycobacterial activity, safety, and pharmacokinetics of AZD5847 in patients with pulmonary tuberculosis. Groups of 15 treatment-naive, sputum smear-positive adults with pulmonary tuberculosis were randomly assigned to receive AZD5847 at one of four doses (500 mg once daily, 500 mg twice daily, 1,200 mg once daily, and 800 mg twice daily) or daily standard chemotherapy. The primary efficacy endpoint was the mean daily rate of change in the log 10 number of CFU of M. tuberculosis per milliliter of sputum, expressed as the change in log 10 number of CFU per milliliter of sputum per day. The mean 14-day activity of the combination of isoniazid, rifampin, ethambutol, and pyrazinamide (−0.163 log 10 CFU/ml sputum/day; 95% confidence interval [CI], −0.193, −0.133 log 10 CFU/ml sputum/day) was consistent with that found in previous studies. AZD5847 at 500 mg twice daily significantly decreased the number of CFU on solid medium (−0.039; 95% CI, −0.069, −0.009; P = 0.0048). No bactericidal activity was detected at doses of AZD5847 of 500 mg once daily (mean early bactericidal activity [EBA], 0.02 [95% CI, −0.01, 0.05]), 1,200 mg once daily (mean EBA, 0.02 [95% CI, −0.01, 0.05]), and 800 mg twice daily (mean EBA, 0.02 [95% CI, −0.01, 0.05]). AZD5847 at doses of both 500 mg and 800 mg twice daily also showed an increase in the time to a positive culture in MGIT liquid culture medium. Two serious adverse events (grade 4 thrombocytopenia and grade 4 hyperbilirubinemia) occurred in patients receiving AZD5847 at higher doses. AZD5847 dosed twice daily kills tubercle bacilli in the sputum of patients with pulmonary tuberculosis and has modest early bactericidal activity. (This study has been registered at ClinicalTrials.gov under registration no. NCT01516203.)
- 1 March 2016
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 20 (3) , 290-294
Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults
Drug-resistant tuberculosis (DR-TB) is a growing public health problem, and for the first time in decades, new drugs for the treatment of this disease have been developed. These new drugs have prompted strengthened efforts in DR-TB clinical trials research, and there are now multiple ongoing and planned DR-TB clinical trials. To facilitate comparability and maximise policy impact, a common set of core research definitions is needed, and this paper presents a core set of efficacy and safety definitions as well as other important considerations in DR-TB clinical trials work. To elaborate these definitions, a search of clinical trials registries, published manuscripts and conference proceedings was undertaken to identify groups conducting trials of new regimens for the treatment of DR-TB. Individuals from these groups developed the core set of definitions presented here. Further work is needed to validate and assess the utility of these definitions but they represent an important first step to ensure there is comparability in clinical trials on multidrug-resistant TB.
- 1 March 2016
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 20 (3) , 290-294
Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults
Drug-resistant tuberculosis (DR-TB) is a growing public health problem, and for the first time in decades, new drugs for the treatment of this disease have been developed. These new drugs have prompted strengthened efforts in DR-TB clinical trials research, and there are now multiple ongoing and planned DR-TB clinical trials. To facilitate comparability and maximise policy impact, a common set of core research definitions is needed, and this paper presents a core set of efficacy and safety definitions as well as other important considerations in DR-TB clinical trials work. To elaborate these definitions, a search of clinical trials registries, published manuscripts and conference proceedings was undertaken to identify groups conducting trials of new regimens for the treatment of DR-TB. Individuals from these groups developed the core set of definitions presented here. Further work is needed to validate and assess the utility of these definitions but they represent an important first step to ensure there is comparability in clinical trials on multidrug-resistant TB.
- Open Access
- 1 March 2016
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 22 (3)
Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis
Two new drugs—bedaquiline and delamanid—have recently been approved by stringent regulatory authorities to treat multidrug-resistant tuberculosis (TB) and recommended by the World Health Organization for use under defined programmatic conditions. Introducing the medications in TB programs worldwide has not kept pace with the need for these drugs. In response, the DR-TB STAT (Drug-Resistant TB Scale-up Treatment Action Team) task force was formed in April 2015 to monitor progress and help overcome challenges. Information was collected from multiple sources and assessed monthly. Some progress has been made in introducing bedaquiline: as of October 2015, a total of 1,258 persons were on the medication under programmatic conditions. For delamanid, >100 patients, but few under programmatic conditions, have received the medication. Coordinated global action might help assist making these medications accessible for persons who need them most.
- 1 March 2016
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 22 (3)
Open AccessGlobal Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis
Two new drugs—bedaquiline and delamanid—have recently been approved by stringent regulatory authorities to treat multidrug-resistant tuberculosis (TB) and recommended by the World Health Organization for use under defined programmatic conditions. Introducing the medications in TB programs worldwide has not kept pace with the need for these drugs. In response, the DR-TB STAT (Drug-Resistant TB Scale-up Treatment Action Team) task force was formed in April 2015 to monitor progress and help overcome challenges. Information was collected from multiple sources and assessed monthly. Some progress has been made in introducing bedaquiline: as of October 2015, a total of 1,258 persons were on the medication under programmatic conditions. For delamanid, >100 patients, but few under programmatic conditions, have received the medication. Coordinated global action might help assist making these medications accessible for persons who need them most.
- 1 February 2016
- Published by Elsevier in The Lancet HIV
- Vol. 3 (3) , e107-e108
The tuberculosis emergency in eastern Europe
- 1 February 2016
- Published by Elsevier in The Lancet HIV
- Vol. 3 (3) , e107-e108
The tuberculosis emergency in eastern Europe
- 1 December 2015
- Published by Elsevier in The Lancet
- Vol. 386 (10010) , e48-e50
No one with HIV should die from tuberculosis
- 1 December 2015
- Published by Elsevier in The Lancet
- Vol. 386 (10010) , e48-e50
No one with HIV should die from tuberculosis
- 1 October 2015
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 15 (10) , 1131
Compassionate and optimum use of new tuberculosis drugs
- 1 October 2015
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 15 (10) , 1131
Compassionate and optimum use of new tuberculosis drugs